Transcription factor Sp7 (SP7)

Transcription factor Sp7 (SP7), also known as Osterix (OSX), is a bone-specific zinc finger transcription factor that is an essential and evolutionarily conserved master regulator of osteoblast differentiation and bone formation[1][2][4]. SP7 acts downstream of Runx2 and, together with other transcription factors such as Dlx5, drives the commitment of mesenchymal stem cells toward the osteoblastic lineage instead of chondrogenesis or formation of other tissues[1][2][3][4]. The protein contains three C2H2-type zinc finger domains and is part of the Sp family. Its role is tightly regulated at multiple levels, such as by microRNAs, post-translational modifications, and protein-protein interactions. Mutations in the SP7 gene cause severe skeletal phenotypes in mice and are strongly associated with human diseases involving bone mineral density, including osteogenesis imperfecta and osteoporosis[1][4]. There are currently no approved drugs that directly target SP7, but its expression and regulatory networks are important targets in bone biology research and skeletal disease modeling[1][4].

Other names

OsterixOSxzinc finger protein osterixosterixOI11OI12Sp7 transcription factorSP7OSX

Not applicable; no approved drugs targeting SP7. Experimental modulation: regulation by upstream signaling (e.g., Bone morphogenetic protein 2/BMP2, Dlx5, Runx2), indirect inhibition by p53, microRNAs, TNF pathway, negative regulation by RIOX1[1][2].